Source: NewScientist.com news service
Posted: September 25, 2006
Summary:
The first clinical safety trial of a purified human fetal stem cell product is about to begin in the US for a rare and fatal childhood brain disease called Batten’s disease – also known as neuronal ceroid lipofuscinosis (NCL). There is currently no alternative treatment for the disease. The trial could lead to neural stem cell transplants to treat a range of brain and spinal cord disorders.
Commentary: Hopefully this trial will be successful in treating Batten's Diseases and also provide scientists with valuable information and insight into how stem cells could be used to treat other nervous system conditions, diseases and disorders.
No comments:
Post a Comment